Emil D. Kakkis, President & CEO at Ultragenyx Pharmaceutical Inc. (RARE), sold 30,000 shares at $96.82 ($2.9M) on 2020-11-02, disclosed to the SEC on 2020-11-04.
Open-market sale of $2.9M RARE by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| RARE | SELL | 2024-12-31 | $990K | — | Filing → |
| RARE | SELL | 2024-12-11 | $414K | — | Filing → |
| RARE | SELL | 2024-09-05 | $1.1M | — | Filing → |